Enhancement of anticancer effects by HSV-TK potentiators and evaluation of navel liposome vectors in MSV-TK/prodding gene therapy

HSV-TK增强剂增强抗癌作用以及MSV-TK/刺激基因治疗中脐脂质体载体的评价

基本信息

  • 批准号:
    12672210
  • 负责人:
  • 金额:
    $ 2.11万
  • 依托单位:
  • 依托单位国家:
    日本
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
  • 财政年份:
    2000
  • 资助国家:
    日本
  • 起止时间:
    2000 至 2001
  • 项目状态:
    已结题

项目摘要

In cancer gene therapy trials, herpes simplex virus-specific thymidine kinase (HSV-TK) has been used as a suicide gene in the presence of ganciclovir (GCV) or acyclovir (ACV). Two diterpenoids, scopadulciol (SDC) and ponicidin (PND), stimulated selectively the HSV-TK enzymatic activity. Thus, we studied the potentiation of GCV/ACV toxicity by these compounds in HSV-TK-expressing cancer cells. The results obtained were as follows:1) Transfectants: Human cancer cells were transfected with the plasmid containing HSV-l tk gene. After cloning, stably HSV-TK-expressing (TK^+) cell clones were obtained. These transfectants showed the ability of forming tumors in nude mice.2) In vivo anticancer effects: The in vivo growth of TK^+ cells was significantly inhibited by coadministration of SDC/PND and ACV, or of SDC/PND and GCV, compared with single administration of ACV or GCV in spite of lower doses.3) Bystander effects: The abilities of SDC and PND to potentiate the bystander effects of the products were determined in both in vitro and in vivo systems. In vitro combined use of SDC/PND. With ACV/GCV rendered tumor cells more sensitive to the prodrugs as compared with the prodrug only in 1 to 20% of TK^+ cells. In the in vivo experiments using nude mice injected with 3 or 10% TK^+ cells, significant reduction in tumor volume was observed in mice treated with drug combinations as compared with those treated with the produg only.4) Toxicity and efficacy: No toxicity of both SDC and PND was seen in mice even at a dose 10-fold higher than that used in the in vivo experiments. SDC has more potent effects than PND, and the possibility for stable supply from organ cultures of the plant.5) Evaluation of the efficiency of liposome vectors: Transfection efficiency of the gene by cationic liposome was increased in the presence of soybean-derived sterylglucoside. The liver targeting was also improved by this liposome.
在癌症基因治疗试验中,单纯疱疹病毒特异性胸苷激酶(单纯疱疹病毒特异性胸苷激酶)已被用作更昔洛韦(GCV)或阿昔洛韦(ACV)存在时的自杀基因。两种二萜,scopadulciol (SDC)和ponicidin (PND)选择性地刺激HSV-TK酶活性。因此,我们研究了这些化合物在表达hsv - tk的癌细胞中增强GCV/ACV毒性。结果如下:1)转染:用含有hsv - ltk基因的质粒转染人癌细胞。克隆后获得稳定表达hsv -TK (TK^+)的细胞克隆。这些转染物在裸鼠体内显示出形成肿瘤的能力。2)体内抗癌作用:与单独给药ACV或GCV相比,SDC/PND与ACV或SDC/PND与GCV联合给药可显著抑制TK^+细胞的体内生长,尽管剂量较低。3)旁观者效应:在体外和体内系统中测定了SDC和PND增强产品旁观者效应的能力。体外联合使用SDC/PND。与前药相比,ACV/GCV使肿瘤细胞仅在1 - 20%的TK^+细胞中对前药更敏感。在给裸鼠注射3%或10% TK^+细胞的体内实验中,与仅用produg治疗的小鼠相比,用药物联合治疗的小鼠肿瘤体积显著减少。4)毒性和功效:即使给药剂量比体内实验高10倍,SDC和PND对小鼠均无毒性。SDC比PND具有更强的作用,并且有可能从植物的器官培养物中稳定供应。5)脂质体载体效率评价:在大豆甾醇苷存在的情况下,阳离子脂质体对基因的转染效率提高。该脂质体也提高了肝脏的靶向性。

项目成果

期刊论文数量(13)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
K.Hayashi, T.Hayashi: "Recent Development in chemical and Pharmaceutical Sciences"Transworld Research Network(in press). (2002)
K.Hayashi、T.Hayashi:“化学和制药科学的最新发展”Transworld Research Network(正在出版)。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
K.Hayashi, T.Hayashi, H.-D.Sun, Y.takeda: "Potentiation of ganciclovir in herpes simpled virus thymidine kinase/ganciclovir administration system by ponicidin"Cancer Gene Therapy. 7(1). 45-52 (2000)
K.Hayashi、T.Hayashi、H.-D.Sun、Y.takeda:“通过波尼西丁对单纯疱疹病毒胸苷激酶/更昔洛韦给药系统中更昔洛韦的增强作用”癌症基因治疗。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
S.H.Hwang, K.Hayashi, K.Takayama, Y.Maitani: "Liver-targeted gene taransfer into a human hepatoblastoma cell line and in vivo by steryglueoside-containing cationic liposomes"Gene Therapy. 8(16). 1276-1280 (2001)
S.H.Hwang、K.Hayashi、K.Takayama、Y.Maitani:“通过含有甾醇糖苷的阳离子脂质体将肝脏靶向基因转移到人肝母细胞瘤细胞系中并在体内进行”基因治疗。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
K.Hayashi,T.Hayashi,H.D.Sun and Y.Takeda: "Potentiation of ganciclovir in herpes simplex virus thymidine Kinase/ganciclovir administration system by ponicidin"Cancer Gene Therapy. 7巻1号. 45-52 (2000)
K.Hayashi、T.Hayashi、H.D.Sun 和 Y.Takeda:“通过波尼西丁对单纯疱疹病毒胸苷激酶/更昔洛韦给药系统的增强”癌症基因治疗,第 7 卷,第 1. 45-52 期(2000 年)。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

HAYASHI Kyoko其他文献

HAYASHI Kyoko的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('HAYASHI Kyoko', 18)}}的其他基金

Characterization of the NS1 mutants induced by a chemical substance
化学物质诱导的 NS1 突变体的表征
  • 批准号:
    25460206
  • 财政年份:
    2013
  • 资助金额:
    $ 2.11万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Attenuatio of influenza virus by drug treatment and elucidation of mechanism of the attenuation
药物治疗对流感病毒的减毒作用及减毒机制的阐明
  • 批准号:
    21590153
  • 财政年份:
    2009
  • 资助金额:
    $ 2.11万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Evaluation of anti-human coronavirus agents
抗人类冠状病毒药物的评价
  • 批准号:
    16590434
  • 财政年份:
    2004
  • 资助金额:
    $ 2.11万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Research on the potentiators of HSV-specific thymidine kinase for the purpose of their application to gene therapy and antiviral therapy
HSV特异性胸苷激酶增强剂的研究及其在基因治疗和抗病毒治疗中的应用
  • 批准号:
    09672276
  • 财政年份:
    1997
  • 资助金额:
    $ 2.11万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)

相似海外基金

Investigating the role of long-term latent herpes simplex virus infection on APOE4-associated Alzheimer's disease pathogenesis
研究长期潜伏的单纯疱疹病毒感染对 APOE4 相关阿尔茨海默病发病机制的作用
  • 批准号:
    10740641
  • 财政年份:
    2023
  • 资助金额:
    $ 2.11万
  • 项目类别:
Identification of innate immune pathways as targets for immunomodulatory therapy in herpes simplex virus encephalitis
鉴定先天免疫途径作为单纯疱疹病毒脑炎免疫调节治疗的靶点
  • 批准号:
    478442
  • 财政年份:
    2023
  • 资助金额:
    $ 2.11万
  • 项目类别:
    Operating Grants
Role of receptor-interacting serine/threonine-protein kinase 3 (RIPK3) in Herpes Simplex Virus (HSV) Encephalitis
受体相互作用丝氨酸/苏氨酸蛋白激酶 3 (RIPK3) 在单纯疱疹病毒 (HSV) 脑炎中的作用
  • 批准号:
    10645451
  • 财政年份:
    2023
  • 资助金额:
    $ 2.11万
  • 项目类别:
Mechanisms of Synergy between Oncolytic Herpes Simplex Virus and Trabectedin in Pediatric Bone Sarcomas
溶瘤单纯疱疹病毒与曲贝替定治疗小儿骨肉瘤的协同作用机制
  • 批准号:
    10607503
  • 财政年份:
    2023
  • 资助金额:
    $ 2.11万
  • 项目类别:
Designing a novel vaccine against herpes simplex virus 2
设计针对单纯疱疹病毒 2 的新型疫苗
  • 批准号:
    488762
  • 财政年份:
    2023
  • 资助金额:
    $ 2.11万
  • 项目类别:
    Operating Grants
An R2 non-neuroinvasive herpes simplex virus type 2 vaccine
R2 非神经侵袭性单纯疱疹病毒 2 型疫苗
  • 批准号:
    10698921
  • 财政年份:
    2023
  • 资助金额:
    $ 2.11万
  • 项目类别:
Mechanisms of endogenous retrovirus-mediated antiviral immunity against genital herpes simplex virus 2 infection and disease.
内源性逆转录病毒介导的针对生殖器单纯疱疹病毒2感染和疾病的抗病毒免疫机制。
  • 批准号:
    463342
  • 财政年份:
    2022
  • 资助金额:
    $ 2.11万
  • 项目类别:
    Operating Grants
Analysis of the mechanism of nuclear compartment remodeling by herpes simplex virus.
单纯疱疹病毒核区室重塑机制分析
  • 批准号:
    22K15468
  • 财政年份:
    2022
  • 资助金额:
    $ 2.11万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Temporal Functions of Interferon Lambda Signaling During Acute and Recurrent Herpes Simplex Virus Type 1 Skin Infection
急性和复发性单纯疱疹病毒 1 型皮肤感染期间干扰素 Lambda 信号传导的时间功能
  • 批准号:
    10536270
  • 财政年份:
    2022
  • 资助金额:
    $ 2.11万
  • 项目类别:
A novel prophylactic and therapeutic vaccine for ocular herpes simplex virus infections
一种针对眼部单纯疱疹病毒感染的新型预防和治疗疫苗
  • 批准号:
    10482237
  • 财政年份:
    2022
  • 资助金额:
    $ 2.11万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了